Raymond James & Associates’s MiMedx Group MDXG Stock Holding History

Raymond James & Associates’s Portfolio MDXG Stock Details MDXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-36,000	Closed	-$7K	–	4214
2021 Q4	$7K	Sell	36,000 -4,000	-10%	-$27.8K	﹤0.01%	4088
2021 Q3	$21K	Buy	40,000 +20,000	+100%	+$225K	﹤0.01%	4003
2021 Q2	$26K	Hold	20,000	–	–	﹤0.01%	3963
2021 Q1	$8K	Buy	+20,000	New	+$193K	﹤0.01%	3962
2017 Q4	–	Sell	-69,600	Closed	-$17K	–	3490
2017 Q3	$17K	Buy	69,600 +3,500	+5%	+$51.9K	﹤0.01%	3327
2017 Q2	$73K	Buy	+66,100	New	+$882K	﹤0.01%	3151

Other funds holding MDXG

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Trigran Investments Northbrook, Illinois $418M AUM 3.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCMI

Paradigm Capital Management Inc Albany, New York $2.61B AUM 78.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PAIM

Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Raymond James & Associates's MDXG Position: Q3 2024 in Review

Raymond James & Associates reduced its MiMedx Group (MDXG) stake by 6.7% in Q3 2024, selling an estimated $6.74K and leaving 14,242 shares worth $84.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3802.

Raymond James & Associates first reported a position in MDXG in Q4 2014 and has held it in 31 quarters since. The position peaked at $2.65M in Q2 2017. 194 funds tracked by Wall St. Rank hold MDXG as of Q3 2024.

Raymond James & Associates held 14,242 shares of MiMedx Group worth $84.2K as of Q3 2024.
Raymond James & Associates sold 1,017 MiMedx Group shares in Q3 2024, an estimated $6.74K.
MiMedx Group made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3802 holding.
Raymond James & Associates first reported a position in MiMedx Group in Q4 2014 and has held it in 31 quarters since.
Raymond James & Associates's MiMedx Group position peaked at $2.65M in Q2 2017.
194 funds tracked by Wall St. Rank held MiMedx Group as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.